anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain a depilation preventing and hair growth tonic, by blending an ethanol extract of Ganoderma lucidum Karst. prepared by adding the Ganoderma lucidum Karst. to ethanol as an active ingredient, capable of preventing depilation, dandruff or itching and promoting the hair growth. CONSTITUTION:A depilation preventing and hair growth tonic, obtained by blending ethanol extract of Ganoderma lucidum Karst. prepared by adding 1-70pts.wt. Ganoderma lucidum Karst. to 100pts.wt. ethanol as an active ingredient, preferably blending the above-mentioned active ingredient in a blend of 100pts.wt. ethanol with 10-70pts.wt. SAKE (Japanese rice wine), particularly 55pts.wt. ethanol with 30pts.wt. SAKE and having the above-mentioned effects. The amount of the above-mentioned depilation preventing and hair growth tonic used is preferably about 3g per month expressed in terms of the Ganoderma lucidum Karst.
A method of associating objects using proximity sensing is described. Each of the objects to be associated is adapted to emit signals using a short-range communications technology. Each of the objects continually emits a signal comprising an identifier of that object. A plurality of detecting devices detect signals emitted from the objects. Distances between the emitting object and the detecting device are determined for each of the detected signals. Clusters of the objects are determined from the determined distances. An attempt is then made to associate each cluster with an event. For each cluster associated with the event, the duration and composition of the cluster are determined. Devices suitable for acting as detecting devices and objects are described, as is a computer system for carrying out the method.
According with the investigators previously reported selection flow-chart , patients suitable for surgical approach were those with HCC without ascites, without or with esophageal varices for which preoperative endoscopic eradication could be carried out successfully, and with serum bilirubin level lower than 1.5 mg/dl. Potential candidates to systematic segmental or subsegmental resection by IOUS-guided finger compression were considered patients with single HCC located in one or 2 adjacent segments without portal thrombosis, and anyway not demanding for its complete removal a sectional resection or wider.
Cadonilimab will be administered at a selected dose every 4 weeks (q4w). AK112 will be administed at a fixed dose every 2 weeks (q2w). Nab-paclitaxel and gemcitabine will be administed at 125mg/m2 d1, d8, d15 q4w, and 1000mg/m2 d1, d8, d15 q4w, intravenously respectively.
BACKGROUND: Existing literature suggests that sarcopenia is a highly prevalent condition in older people. However, most studies to date reporting data on its prevalence have been mainly carried out in Western countries, while data on sarcopenia in Africa is scarce. With this systematic review and meta-analysis, we aimed to determine the prevalence of sarcopenia in African countries and to explore potential factors that could explain higher or lower prevalence of this condition in Africa.
METHODS: Major databases for studies reporting data on sarcopenia in African countries were searched from inception to June 2023. We conducted a meta-analysis of the prevalence [and 95% confidence intervals (95% CIs)] of sarcopenia in Africa, applying a random effect model. Several sensitivity and meta-regression analyses were run.
RESULTS: Among 147 articles initially screened, six articles (with seven cohorts) including a total of 10,656 participants were included. Mean age of participants was 66.9 years, and the majority were female (58.1%). The weighted prevalence of sarcopenia in the selected countries of Africa was 25.72% (95%CI: 18.90-32.55). This outcome was characterized by a high heterogeneity (I2 = 99%) and by publication bias. Among the factors investigated, sarcopenia was lower when assessed using only one anthropometric measure, or in South Africa.
CONCLUSION: Sarcopenia is a prevalent condition in Africa and thus research regarding this topic is a public health priority. Future studies that cover African countries for which data are not available and using standardized criteria are needed.
Only persons trained in the administration of general anesthesia should administer Desflurane, USP, Liquid for Inhalation. Only a vaporizer specifically designed and designated for use with desflurane should be utilized for its administration. Facilities for maintenance of a patent airway, artificial ventilation, oxygen enrichment, and circulatory resuscitation must be immediately available.

Desflurane, USP, Liquid for Inhalation is administered by inhalation. The administration of general anesthesia must be individualized based on the patient’s response. Hypotension and respiratory depression increase as anesthesia with Desflurane, USP, Liquid for Inhalation is deepened. The minimum alveolar concentration (MAC) of Desflurane, USP, Liquid for Inhalation decreases with increasing patient age. The MAC for Desflurane, USP, Liquid for Inhalation is also reduced by concomitant N 2O administration  (See Table 1) . The dose should be adjusted accordingly. The following table provides mean relative potency based upon age and effect of N 2O in predominately ASA physical status I or II patients. 

Benzodiazepines and opioids decrease the MAC of Desflurane, USP, Liquid for Inhalation  [See Drug Interactions (7.1, Table 3)] . Desflurane, USP, Liquid for Inhalation also decreases the doses of neuromuscular blocking agents required [See Drug Interactions (7.2, Table 4)] . The dose should be adjusted accordingly.
The invention discloses a pharmaceutical composition for clearing influenza B virus based on CRISPR-Cas13a and application thereof. The invention belongs to the technical field of biology, and particularly relates to a pharmaceutical composition for clearing influenza B virus based on CRISPR-Cas13a and application thereof. The recombinant vector of the invention is an expression vector containing a crRNA expression cassette, wherein the target of the crRNA is PA and/or M1 genes of influenza B virus. The constructed recombinant vector and the jetOPTIMUS cationic polymer nano material are combined to form the influenza B virus inhibitor, so that the replication of a virus genome and the expression of a virus protein can be effectively inhibited. Through qPCR verification, the clearance rate of the recombinant vector to the influenza B virus can reach 87.05% at most. The invention provides a new strategy for preventing and treating influenza B virus and can also provide technical support for the research and development of other virus infection treatment methods.
In a placebo controlled study in which naltrexone hydrochloride was administered to obese subjects at a dose approximately five-fold that recommended for the blockade of opiate receptors (300 mg per day), 19% (5/26) of naltrexone hydrochloride recipients and 0% (0/24) of placebo-treated patients developed elevations in serum transaminases (i.e. peak ALT values ranging from 121 to 532; or 3 to 19 times their baseline values) after three to eight weeks of treatment. The patients involved were generally clinically asymptomatic, and the transaminase levels of all patients on whom follow-up was obtained returned to (or toward) baseline values in a matter of weeks.

Transaminase elevations were also observed in other placebo controlled studies in which exposure to naltrexone hydrochloride at doses above the amount recommended for the treatment of alcoholism or opioid blockade consistently produced more numerous and more significant elevations of serum transaminases than did placebo. Transaminase elevations occurred in 3 of 9 patients with Alzheimer's Disease who received naltrexone hydrochloride (at doses up to 300 mg/day) for 5 to 8 weeks in an open clinical trial.

To report SUSPECTED ADVERSE REACTIONS, contact AvKARE, Inc. at 1-855-361-3993; email drugsafety@avkare.com; or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
The invention discloses an external medicament for treating radioactive wet dermatitis. Radioactive wet skin injury belongs to traditional Chinese medicine fields of burn and scald. The medicament is composited according to the theory of traditional Chinese medicine. The medicament is prepared from the following medicinal materials by weight: 15g of coptis root, 15g of amur corktree bark, 20g of rhubarb, 10g of dahurian angelica root and 10g of catechu. The medicament is prepared by the following steps: adding the medicinal materials into 200ml of clear water; soaking for 1 hour, and decocting for 30 minutes; decocting at a high concentration to 100ml; filtering, filling and sterilizing for later use. During treatment, a local skin lesion is treated, aseptic normal saline is used for cleaning the wound surface to clean seepage, decrustation and necrotic tissues on the skin lesions, and the liquid medicament is smeared by 4-6 times each day, one course of treatment lasting force every two weeks. Gauze can be used for performing continuous wet compressing as applicable for body position or environment. The Chinese medicinal preparation has the effects of clearing away heat, drying dampness, discharging fire and detoxifying. The medicament is prepared from easily-available medicinal raw materials, is low in cost, has a remarkable effect, is easy for patients to accept, and can be popularized and applied conveniently in clinic.
BACKGROUND: Supervised exercise training is recommended for people with peripheral artery disease (PAD), yet it remains underutilized. Home-based exercise programs (HBEPs) are a potential alternative. The aim of this study was to assess the feasibility of conducting a full scale trial of a 12-week HBEP for people living with symptomatic PAD.
METHODS: In a randomized feasibility trial, patients with intermittent claudication were allocated to either an HBEP or a nonexercise control. The HBEP group was given a Fitbit to use during a 12-week exercise program comprising of personalized step goals and a resistance-based circuit to be undertaken at home twice weekly. The primary outcome was feasibility, assessed via eligibility, recruitment, attrition, tolerability, and adherence. Acceptability was assessed via semistructured interviews. Secondary analysis was undertaken to determine the feasibility of collecting clinical outcome data.
RESULTS: 188 people were screened, 133 were eligible (70.7%), 30 were recruited (22.6%) and one withdrew (3.33%). Mean adherence to the daily step goal was 53.5% (range = 29.8-90.5%), and 58.6% of prescribed circuits were completed of which 56.4% were at the desired intensity. Six adverse events were recorded, 3 of which were related to study involvement. No significant differences were observed in exploratory outcomes. Small clinically important differences were seen in walking speed and pain-free treadmill walking distance which should be confirmed or refuted in a larger trial.
CONCLUSIONS: The HBEP was feasible and well tolerated, with successful recruitment and minimal attrition. The intervention was acceptable, with walking seen as more enjoyable than circuit exercise. The WALKSTRONG program may be suitable for those who will not, or cannot, take part in supervised exercise outside of the home.
Patients will receive a course of 10 chiropractic treatments over a 14 week period. They are to also maintain their usual medical care as prescribed by their physician, but are not to begin any new therapies.
We have previously reported that inherited mutations of TP53, which causes the premature cancer disorder Li-Fraumeni syndrome (LFS), can promote mitochondrial function both in patients and mouse models. In the course of our follow up studies, we encountered a LFS patient with a long-standing history of fatigue and muscle weakness of unclear etiology. Notably, we observed in vivo evidence of markedly decreased mitochondrial function in her leg skeletal muscle during exercise using noninvasive phosphorus-31 magnetic resonance spectroscopy (31P-MRS), a technique that has previously been used to study patients with primary mitochondrial disorders. The decrease in mitochondrial function was also confirmed by the patients skin fibroblasts in vitro using standard biochemical measurements.

There is growing evidence that nicotinamide adenine dinucleotide (NAD+) homeostasis plays a significant role in maintaining the mitochondria through various mechanisms and that it is possible to improve mitochondrial function by dietary supplementation with the vitamin B3 analogue nicotinamide riboside (NR), an intermediate in the NAD+ salvage pathway. Remarkably, we observed that culturing the LFS patients fibroblasts in medium containing NR rescued the severe deficit in mitochondrial respiration. While continuing our investigations into the molecular mechanism(s) underlying the mitochondrial dysfunction observed in this patient, the in vitro rescue of the respiratory deficiency by NR presents a unique opportunity to investigate whether it can also be observed in vivo using skeletal muscle 31P-MRS. We propose to explore the effect of NR, currently available as a dietary supplement, on in vivo mitochondrial function in this LFS patient.
The invention relates to a technology for preparing a novel oyster shell powder integral preparation and a production method thereof. The preparation is prepared from the following effective components in parts by weight: 30 parts of calcined oyster shell, 30 parts of astragalus, 30 parts of Chinese ephedra root, and 15 parts of blighted wheat. The production process comprises the following steps of supersonic airflow pulverizing, alcohol-water extraction, supersonic pulverizing extraction, decoction and concentration, nano-grinding, high-pressure homogenization, nano-particle preparation and the like. The technology pays attention to the application of the advantages of multi-collaboration multi-target and the like represented by a nano-carrier combination technology. After the technology is applied to production in scale, the production cost can be greatly reduced, the product quality can be greatly improved, and the targeting and sustained release performance of the medicament can be stronger. The preparation can be administrated internally and externally simultaneously, can be taken in four time segments respectively according to midnight-noon ebb-flow and human body qi-blood flowing rule, also can be prepared to form a film-forming agent and transdermal agent to be applied to different positions of a human body respectively according to the midnight-noon ebb-flow and human body qi-blood flowing rule, and can be directly absorbed through skin.
This study will evaluate the clinical efficacy of the BTL-899 and HPM-6000UF devices in combination for non-invasive strengthening of the core muscles and overall improvement in quality of life in female patients after childbirth. The study is a prospective, multicenter single-arm, open-label, interventional study. The subjects will be enrolled and assigned into a single study group. Subjects will be required to complete seven (7) treatment visits and two (2) follow-up visits - 1 month and 3 months after the final treatment.

At the baseline visit, medical history will be assessed. Inclusion and exclusion criteria will be verified, and informed consent will be signed. Digital photographs will be taken, waist circumference will be measured, abdominal muscle strength will be measured with a pressure biofeedback device.

The two devices will be used separately in two different treatments. However, one treatment visit can comprise both treatments. The BTL-899 will be applied over the abdomen, and the device will induce visible muscle contractions along with mild heating of the muscles. Four (4) treatments five (5) to (10) days apart will be delivered. The HPM-6000UF device will induce pelvic floor muscle contractions. Six (6) treatments 2-4 days apart will be delivered. There will be three (3) visits where both treatments will be applied consecutively, starting with BTL-899, followed by the therapy with HPM-6000UF.
Consecutive patients with stable multiple sclerosis are being recruited from the neurological services of Social Security Mexican Institute (IMSS) at the National Medical Center (CMN) "Siglo XXI" Specialties Hospital over the period of 1 year. Of those meeting inclusion criteria, 24 will be selected for the study. After signing an informed consent, they will be randomized into 12 for the intervention arm and 12 for the placebo arm. All patients will receive capsules for daily consumption according to their assignment, with no visible difference between capsules. Dosage will be 6.5-7.5 mg/kg to a limit of 50 mg. These capsules will be taken for a period of 22 weeks. A battery of neuropsychological tests will be administered at baseline, after 22 weeks, and after an additional 22 weeks of follow-up to assess cognitive performance and motor function. Emotional state will be assessed with the Beck Depression Inventory at each of the three afore mentioned points.

After the follow-up period, all test results will be analyzed and compared to determine the efficacy and safety of 4-aminopyridine on the cognitive performance and motor function of patients. Mann-Whitney U will be used for statistical analysis.
Implantable bioelectrodes for regulating and monitoring biological behaviors have become indispensable medical devices in modern healthcare, alleviating pathological symptoms such as epilepsy and arrhythmia, and assisting in reversing conditions such as deafness and blindness. In recent years, developments in the fields of materials science and biomedical engineering have contributed to advances in research on implantable bioelectrodes. However, the foreign body reaction (FBR) is still a major constraint for the long-term application of electrodes. In this paper, four types of commonly used implantable bioelectrodes are reviewed, concentrating on their background, development, and a series of complications caused by FBR after long-term implantation. Strategies for resisting FBRs are then devised in terms of physics, chemistry, and nanotechnology. We analyze the major trends in the future development of implantable bioelectrodes and outline some promising research to optimize the long-term operational stability of electrodes. Although current implantable bioelectrodes have been able to achieve good biocompatibility, low impedance, and low mechanical mismatch and trauma, these devices still face the challenge of FBR. Resistance to FBR is still the key for the long-term effectiveness of bioelectrodes, and a better understanding of the mechanisms of FBR, as well as miniaturization, long-term passivation, and coupling with gene therapy may be the way forward for the next generation of implantable bioelectrodes.
Tetrabenazine is a drug that is administered orally. This is 25 mg tablets, divisible into 2.
BACKGROUND: Diarrheal disease is a leading cause of childhood morbidity and mortality globally. Household water, sanitation, and handwashing (WASH) interventions can reduce exposure to diarrhea-causing pathogens, but meteorological factors may impact their effectiveness. Information about effect heterogeneity under different weather conditions is critical to refining these targeted interventions.
OBJECTIVES: We aimed to determine whether temperature and precipitation modified the effect of low-cost, point-of-use WASH interventions on child diarrhea.
METHODS: We analyzed data from a trial in rural Bangladesh that compared child diarrhea prevalence between clusters (N=720) that were randomized to different WASH interventions between 2012 and 2016 (NCT01590095). We matched temperature and precipitation measurements to diarrhea outcomes (N=12,440 measurements, 6,921 children) by geographic coordinates and date. We estimated prevalence ratios (PRs) using generative additive models and targeted maximum likelihood estimation to assess the effectiveness of each WASH intervention under different weather conditions.
RESULTS: Generally, WASH interventions most effectively prevented diarrhea during monsoon season, particularly following weeks with heavy rain or high temperatures. The PR for diarrhea in the WASH interventions group compared with the control group was 0.49 (95% CI: 0.35, 0.68) after 1 d of heavy rainfall, with a less-protective effect [PR=0.87 (95% CI: 0.60, 1.25)] when there were no days with heavy rainfall. Similarly, the PR for diarrhea in the WASH intervention group compared with the control group was 0.60 (95% CI: 0.48, 0.75) following above-median temperatures vs. 0.91 (95% CI: 0.61, 1.35) following below-median temperatures. The influence of precipitation and temperature varied by intervention type; for precipitation, the largest differences in effectiveness were for the sanitation and combined WASH interventions.
DISCUSSION: WASH intervention effectiveness was strongly influenced by precipitation and temperature, and nearly all protective effects were observed during the rainy season. Future implementation of these interventions should consider local environmental conditions to maximize effectiveness, including targeted efforts to maintain latrines and promote community adoption ahead of monsoon seasons. https://doi.org/10.1289/EHP13807.
PURPOSE:To provide the cosmetic, especially the aqueous transparent cosmetic, containing a specific phospholipid suitable for the cosmetic, little in the irritation of skin, excellent in touch and moisture-retaining property, showing a good appearance, and excellent in storage stability. CONSTITUTION:This cosmetic, especially an aqueous transparent cosmetic, contains a hydroxyphospholipid exhibiting an iodine value of <=30 and a hydroxy group value of <=250. The hydroxyphospholipid is obtained, e.g. by oxidizing a glycerophospholipid originated from a natural substance, or further preferably oxidizing phosphatidyl choline. The total amount of the hydroxyphospholipid is preferably 0.01-30wt.% based on the whole weight of the components of the cosmetic. The hydroxyphospholipid is stable for at least 2-3 years at the ordinary temperature, and is originated from a natural substance showing good hydrophilicity. The prescription of the cosmetic can easily be designed without using a synthetic surfactant other than the phospholipid, whereby the cosmetic is profitable.
UNLABELLED: We report the results of a first-in-human phase 1 clinical study to evaluate TRL1068, a native human monoclonal antibody that disrupts bacterial biofilms with broad-spectrum activity against both Gram-positive and Gram-negative species. The study population consisted of patients with chronic periprosthetic joint infections (PJIs) of the knee or hip, including both monomicrobial and polymicrobial infections, that are highly resistant to antibiotics due to biofilm formation. TRL1068 was administered via a single pre-surgical intravenous infusion in three sequentially ascending dose groups (6, 15, and 30 mg/kg). Concomitant perioperative antibiotics were pathogen-targeted as prescribed by the treating physician. In this double-blinded study, 4 patients were randomized to receive placebo and 11 patients to receive TRL1068 on day 1, as well as targeted antibiotics for 7 days prior to the scheduled removal of the infected implant and placement of an antibiotic-eluting spacer as the first stage of the standard of care two-stage exchange arthroplasty. No adverse events attributable to TRL1068 were reported. TRL1068 serum half-life was 15-18 days. At day 8, the concentration in synovial fluid was approximately 60% of the blood level and thus at least 15-fold above the threshold for biofilm-disrupting activity in vitro. Explanted prostheses were sonicated to release adherent bacteria for culture, with elimination of the implant bacteria observed in 3 of the 11 patients who received TRL1068, which compares favorably to prior PJI treatments. None of the patients who received TRL1068 had a relapse of the original infection by the end of the study (day 169).
CLINICAL TRIALS: This study is registered with ClinicalTrials.gov as NCT04763759.